GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (OSTO:AZN) » Definitions » Cyclically Adjusted PS Ratio

AstraZeneca (OSTO:AZN) Cyclically Adjusted PS Ratio : 6.36 (As of May. 24, 2024)


View and export this data going back to 1999. Start your Free Trial

What is AstraZeneca Cyclically Adjusted PS Ratio?

As of today (2024-05-24), AstraZeneca's current share price is kr1695.00. AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr266.34. AstraZeneca's Cyclically Adjusted PS Ratio for today is 6.36.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted PS Ratio or its related term are showing as below:

OSTO:AZN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.42   Med: 3.87   Max: 6.78
Current: 6.34

During the past years, AstraZeneca's highest Cyclically Adjusted PS Ratio was 6.78. The lowest was 2.42. And the median was 3.87.

OSTO:AZN's Cyclically Adjusted PS Ratio is ranked worse than
86.29% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.115 vs OSTO:AZN: 6.34

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AstraZeneca's adjusted revenue per share data for the three months ended in Mar. 2024 was kr84.619. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr266.34 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted PS Ratio Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.04 4.89 5.51 6.30 5.53

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.19 6.04 5.85 5.53 5.45

Competitive Comparison of AstraZeneca's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.



AstraZeneca Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AstraZeneca's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1695.00/266.34
=6.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=84.619/131.6000*131.6000
=84.619

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 35.767 99.800 47.164
201409 37.281 100.000 49.062
201412 40.535 99.900 53.397
201503 40.914 99.600 54.059
201506 41.209 100.100 54.177
201509 39.316 100.200 51.637
201512 42.966 100.400 56.318
201603 40.313 100.400 52.841
201606 36.782 101.000 47.926
201609 38.403 101.500 49.791
201612 40.617 102.200 52.301
201703 38.060 102.700 48.770
201706 34.622 103.500 44.022
201709 39.397 104.300 49.709
201712 38.176 105.000 47.847
201803 33.678 105.100 42.170
201806 35.808 105.900 44.498
201809 37.677 106.600 46.513
201812 45.736 107.100 56.198
201903 40.243 107.000 49.495
201906 41.757 107.900 50.929
201909 47.403 108.400 57.548
201912 47.873 108.500 58.065
202003 47.637 108.600 57.726
202006 44.496 108.800 53.821
202009 44.398 109.200 53.505
202012 47.198 109.400 56.776
202103 47.411 109.700 56.876
202106 52.367 111.400 61.863
202109 57.006 112.400 66.744
202112 69.894 114.700 80.192
202203 69.793 116.500 78.839
202206 69.286 120.500 75.668
202209 76.854 122.300 82.698
202212 74.555 125.300 78.304
202303 73.059 126.800 75.825
202306 78.808 129.400 80.148
202309 81.658 130.100 82.599
202312 78.659 130.500 79.322
202403 84.619 131.600 84.619

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (OSTO:AZN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AstraZeneca Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (OSTO:AZN) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (OSTO:AZN) Headlines

From GuruFocus